William Blair Has Positive Outlook of ResMed FY2025 Earnings

ResMed Inc. (NYSE:RMD) – Investment analysts at William Blair raised their FY2025 EPS estimates for shares of ResMed in a research report issued to clients and investors on Monday, February 3rd. William Blair analyst M. Andrew now forecasts that the medical equipment provider will earn $9.40 per share for the year, up from their prior forecast of $9.30. The consensus estimate for ResMed’s current full-year earnings is $9.41 per share. William Blair also issued estimates for ResMed’s Q1 2026 earnings at $2.66 EPS, Q2 2026 earnings at $2.80 EPS, Q3 2026 earnings at $2.55 EPS and Q4 2026 earnings at $2.67 EPS.

ResMed (NYSE:RMD) last released its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

A number of other brokerages have also issued reports on RMD. JPMorgan Chase & Co. lifted their price target on shares of ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. The Goldman Sachs Group began coverage on shares of ResMed in a research note on Thursday, January 16th. They set a “buy” rating on the stock. Needham & Company LLC restated a “hold” rating on shares of ResMed in a report on Friday, January 31st. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Finally, UBS Group raised ResMed from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 31st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and a consensus target price of $244.73.

ResMed Trading Up 0.1 %

Shares of RMD stock opened at $240.73 on Wednesday. The stock has a market cap of $35.34 billion, a price-to-earnings ratio of 28.42, a price-to-earnings-growth ratio of 1.69 and a beta of 0.70. The firm’s 50 day moving average price is $240.00 and its two-hundred day moving average price is $236.89. ResMed has a fifty-two week low of $170.56 and a fifty-two week high of $263.05. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be given a $0.53 dividend. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.88%. ResMed’s dividend payout ratio is currently 25.03%.

Insiders Place Their Bets

In related news, Director Witte Jan De sold 796 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the transaction, the director now owns 6,723 shares in the company, valued at $1,672,749.63. This trade represents a 10.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total value of $491,300.00. Following the transaction, the director now owns 81,218 shares of the company’s stock, valued at $19,951,201.70. This trade represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 9,094 shares of company stock worth $2,220,721. 0.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ResMed

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Howard Capital Management Inc. increased its holdings in ResMed by 5.3% during the 4th quarter. Howard Capital Management Inc. now owns 900 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 45 shares in the last quarter. UMB Bank n.a. increased its stake in shares of ResMed by 1.9% in the 3rd quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider’s stock valued at $602,000 after buying an additional 47 shares during the period. Ascent Group LLC increased its stake in shares of ResMed by 1.7% in the 3rd quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider’s stock valued at $714,000 after buying an additional 48 shares during the period. SkyView Investment Advisors LLC increased its stake in shares of ResMed by 2.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider’s stock valued at $637,000 after buying an additional 51 shares during the period. Finally, Wedmont Private Capital increased its stake in shares of ResMed by 2.6% in the 4th quarter. Wedmont Private Capital now owns 2,032 shares of the medical equipment provider’s stock valued at $475,000 after buying an additional 52 shares during the period. 54.98% of the stock is owned by institutional investors and hedge funds.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.